Companies to reveal list price reductions to German authorities
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies that fail to negotiate a price with German health insurers will likely have to disclose discounts or rebates in the 15 countries to be referenced by the arbitration board that will set German prices. The arbitration board says that companies must report the "actual price" in these countries.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.